1933 Industries Inc C.TGIF

Alternate Symbol(s): TGIFF

Healthcare Cannabis

1933 Industries Inc. is a Canada-based cannabis cultivator and producer. The Company is focused on the cultivation and manufacturing of a portfolio of cannabis consumer-packaged goods in a variety of formats for both the wholesale and retail markets. The Company operates through three segments: Alternative Medicine Association LLC (AMA), Infused Mfg LLC (Infused MFG), and Corporate. Its AMA segment is focused on the cultivation and sale of medical and adult use cannabis products. Its Infused MFG segment is focused on the manufacturing of Hemp derived cannabidiol (CBD) products. Its product offerings through its in-house brands, including wholesale flower, pre-rolls, and extracted products under the AMA and Level X brands for the Nevada market; and Canna Hemp, a national CBD brand of wellness products, which include tinctures, gummies, topicals and sports recovery products. The Company owns 91% of AMA, and 100% of Infused MFG LLC Infused.

CSE:TGIF - Post by User

1933 Industries Inc > another bnn article --- Canadian TRENDS! thumbs up please!

<< Previous

Bullboard Posts

Next >>

Comment by meagainon Nov 01, 2021 7:29am

181 Views

Post# 34071941

RE:another bnn article --- Canadian TRENDS! thumbs up please!

jfogarty12 wrote:

Analyst Call of the Week - RBC Capital Markets on Canadian valuations

RBC Capital Markets Analyst Douglas Miehm previewed the third-quarter for some of Canada's major cannabis players in a report to clients earlier this week, noting that valuations remain depressed given the uncertainty on U.S. legalization efforts and weaker-than-expected Q2 results. Miehm expects those valuations to bounce back somewhat amid improving sentiment as COVID-19 restrictions ease, more retail stores opening and various cost-cutting efforts. He sees the valuations for companies like Canopy Growth and Tilray (at 7.1x and 5.7x enterprise value-to-sales multiples respectively) reflecting their potential upside from entering U.S. and international markets, while Sundial’s valuation appears "overdone" due to speculative trading despite having $600 million in cash on its books. Miehm also hiked his retail sales target for 2021 to $4.0 billion from $3.8 billion, while seeing 2022 sales climb to $4.8 billion. "We estimate new product launches, an increased numbers of stores, increased retail store traffic footprint and pricing declines to support the growth of the market, including migration of purchases from the illicit market to the regulated market," Miehm said. Sales of Cannabis 2.0 recreational products such as drinks and edibles should represent 37 per cent of the market by 2022, nearly double from 2020 sales, he estimates.